PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0

• Barbara Kiesewetter,
• Urania Dafni,
• Elisabeth G E de Vries,
• Jorge Barriuso,
• Giuseppe Curigliano,
• Veronica González-Calle,
• Martina Galotti,
• Bishal Gyawali,
• Brian Huntly,
• Ulrich Jaeger,
• Nicola Jane Latino,
• Luca Malcovati,
• Sjoukje Oosting,
• Gert Ossenkoppele,
• Martine Piccart,
• Markus Raderer,
• Lydia Scarfò,
• Dario Trapani,
• Christoph C Zielinski,
• Ruth Wester,
• Panagiota Zygoura,
• Elizabeth Macintyre,
• Nathan I Cherny

Affiliations

Barbara Kiesewetter

1 Medical University of Vienna, Division of Oncology, Department of Medicine I, Vienna, Austria

Urania Dafni

2 National and Kapodistrian University of Athens, Laboratory of Biostatistics, School of Health Sciences, Athens, Greece

Elisabeth G E de Vries

4 University of Groningen, Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands

Jorge Barriuso

5 The University of Manchester, The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, United Kingdom

Giuseppe Curigliano

6 University of Milan, Department of Oncology and Hemato-Oncology, Italy

Veronica González-Calle

8 CIBERONC and Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Servicio de Hematología, Hospital Universitario de Salamanca-IBSAL, Salamanca

Martina Galotti

9 ESMO Head Office, Lugano, Switzerland

Bishal Gyawali

10 Queen’s University, Department of Oncology & Department of Public Health Sciences, Kingston, Canada

Brian Huntly

11 University of Cambridge & Cambridge University Hospitals, Cambridge Stem Cell Institute, Department of Haematology

Ulrich Jaeger

12 Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna, Austria

Nicola Jane Latino

9 ESMO Head Office, Lugano, Switzerland

Luca Malcovati

13 University of Pavia, Department of Molecular Medicine, Pavia, Italy

Sjoukje Oosting

4 University of Groningen, Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands

Gert Ossenkoppele

15 VU University Medical Center, Cancer Center Amsterdam, Department of Hematology, Amsterdam, The Netherlands

Martine Piccart

16 Université Libre de Bruxelles (ULB), Institut Jules Bordet, Brussels, Belgium

Markus Raderer

1 Medical University of Vienna, Division of Oncology, Department of Medicine I, Vienna, Austria

Lydia Scarfò

17 IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Strategic Research Program on CLL, Division of Experimental Oncology, Milan, Italy

Dario Trapani

18 Harvard Medical School, Medical Oncology Department, Dana-Farber Cancer Institute, Boston, United States

Christoph C Zielinski

19 Wiener Privatklinik, Central European Academy Cancer Center, Wien, Austria

Ruth Wester

20 Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, The Netherlands

Panagiota Zygoura

3 Frontier Science Foundation-Hellas, Athens, Greece

Elizabeth Macintyre

21 Université de Paris Cité, Institut Necker Enfants-Malades INEM, Institut National de La Santé Et de La Recherche Médicale (Inserm), Paris, France

Nathan I Cherny

23 Shaare Zedek Medical Center, Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Jerusalem, Israel